drugset
drugset / Press release

Starting co-promotion of the anti-cancer agent “SPRYCEL Tablet 20mg and SPRYCEL Tablet 50mg” (dasatinib) in Japan ®®

2010-12-21 · Otsuka Pharmaceutical Development & Commercialization, Inc. · original otsuka.co.jp ↗

dasatinib anhydrous

Tokyo, Japan -- Bristol-Myers K.K. (Headquarters: Shinjuku-ku, Tokyo; President and CEO: Emmanuel Blin) and Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President: Taro Iwamoto) will start co-promotion activities on the sales of the anti-cancer agent "SPRYCEL Tablet 20mg and SPRYCEL Tablet 50mg" (dasatinib) in Japan on January 1, 2011.st

The release as fetched from its publisher. otsuka.co.jp ↗